Featured News

On July 27, Celiac Disease Foundation CEO, Marilyn G. Geller, will be presenting the “Role of Patient Advocacy in Clinical Trials” on a webinar hosted by the Society for the Study of Celiac Disease.

An analysis by an independent statistician of the ongoing Phase 3 trial for Larazotide has concluded that a substantial number of new patients would have to be added to the existing trial in order to get scientifically meaningful results.

According to a recent analysis, children who have a first-degree relative with celiac disease may be at higher risk of developing the disease before age 10 than previously thought.

The Celiac Disease Foundation was honored to award the first annual Prize for Excellence in Celiac Disease Research to Dr. Joseph Murray. The Foundation was also honored to award the first annual Young Investigator Prize to Dr. Jocelyn Silvester.

“Celiac Disease Symptom Flares are Common During the Postpartum Period,” a study using data from the iCureCeliac® patient registry and co-authored by Marilyn G. Geller, Celiac Disease Foundation CEO, was…

Anokion SA released successful results from their Phase 1 ACeD clinical trial and they will be moving forward with Phase 2 trials later this year.

This educational event is the second in a series of 10 bimonthly programs and is open to healthcare professionals and patients. Registration is required and free to all registrants.

The Celiac Disease Foundation is pleased to announce the establishment of two international celiac disease research prizes to inspire a new generation of researchers whose work in celiac disease will be invaluable.

A recent study identified several biochemical abnormalities associated with testing positive for celiac disease in an antibody test. These biochemical abnormalities could be a predictor of celiac disease and become a tool to reduce delayed diagnosis.

A recent study found that avoidant/restrictive food intake disorder (ARFID) is common among people with celiac disease.